<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178343">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773422</url>
  </required_header>
  <id_info>
    <org_study_id>HIC0710003188</org_study_id>
    <secondary_id>P50AA015632</secondary_id>
    <nct_id>NCT00773422</nct_id>
  </id_info>
  <brief_title>The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse</brief_title>
  <official_title>The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine how medications thought to attenuate the effects of
      alcohol (naltrexone) and smoking cessation medications (varenicline) affect the ability to
      resist smoking and also subsequent ad-lib smoking, following a low-dose alcohol priming
      drink, in non-treatment seeking alcohol-drinking daily smokers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>latency to initiate ad-lib smoking session</measure>
    <time_frame>in the laboratory session</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of cigarettes smoked during the ad-lib period</measure>
    <time_frame>during the laboratory session</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>naltrexone + varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>naltrexone (25mg) + varenicline (2mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>varenicline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>varenicline 2mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone</intervention_name>
    <description>25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).</description>
    <arm_group_label>naltrexone + varenicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>varenicline</intervention_name>
    <description>2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).</description>
    <arm_group_label>naltrexone + varenicline</arm_group_label>
    <arm_group_label>varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages 21-55

          -  ability to read and write in English

          -  alcohol-drinking smokers

        Exclusion Criteria:

          -  any significant current medical conditions that would contraindicate smoking

          -  current DSM-IV abuse or dependence of other substances, other than nicotine
             dependence or alcohol abuse.

          -  positive test result at intake appointments on urine drug screens conducted for
             opiates, cocaine, or benzodiazepines

          -  women who are pregnant or nursing

          -  suicidal, homicidal or evidence of current severe mental illness

          -  participants prescribed any psychotropic drug in the 30 days prior to study
             enrollment

          -  blood donation within the past 6 weeks

          -  individuals seeking treatment for smoking cessation or drinking or have attempted to
             quit smoking or drinking within the past 3 months

          -  specific exclusion for administration of naltrexone not specified above including
             chronic pain conditions necessitating opioid treatment, and evidence of significant
             hepatocellular injury as evidenced by SGOT or SGPT &gt; 3x normal or elevated bilirubin

          -  known allergy to varenicline or taking H2blockers (e.g., Cimetidine)

          -  participation within the past 8 weeks in other studies that involve additive blood
             sampling and/or interventional measures that would be considered excessive in
             combination with the current protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry A McKee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigation, Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 22, 2016</lastchanged_date>
  <firstreceived_date>October 14, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Sherry McKee</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>smoking lapse behavior</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>varenicline</keyword>
  <keyword>naltrexone</keyword>
  <keyword>medication effect on smoking lapse behavior</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
